<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424149</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2015-0008</org_study_id>
    <nct_id>NCT02424149</nct_id>
  </id_info>
  <brief_title>Phenazopyridine for Confirmation of Ureteral Patency</brief_title>
  <acronym>Phenazo</acronym>
  <official_title>Use of Phenazopyridine for Confirmation of Ureteral Patency During Intraoperative Cystoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomized trial subjects will be randomized to receive phenazopyridine
      or no medication prior to pelvic reconstructive procedures that use cystoscopy to confirm
      ureteral patency intraoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Visualize Ureteral Urine Flow Intraoperatively Measured by Timing in the Operating Room</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Timing was performed in the operating room. Time to visualize urine efflux was started at insertion of the cystoscope into the bladder, the time was considered complete when both ureteral orifices had displayed urine efflux.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Confidence Measured by a Survey</measure>
    <time_frame>day of surgery (day 0)</time_frame>
    <description>Surgeon response to the question: &quot;I am confident that ureteral injury was ruled out in this patient&quot; on a 5-point Likert scale where 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Interventions: Measured by Use of IV Fluids, IV Lasix, IV Methylene Blue, or Ureteral Stent Placement in OR</measure>
    <time_frame>day of surgery (day 0)</time_frame>
    <description>this is a composite measure and will be reported as a single value for each arm as number of additional interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Urethral Discomfort Measured by Pain Scales</measure>
    <time_frame>post operative day 1</time_frame>
    <description>Measured prior to catheter removal using a 10 point visual analog pain scale: Zero represented no pain, Ten represented the most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial of Void Results</measure>
    <time_frame>Day of hospital discharge</time_frame>
    <description>Number of subjects that failed a back-filled trial of void on the day of hospital discharge, up to 2 days after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Cystoscopy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No preoperative phenazopyridine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative phenazopyridine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine</intervention_name>
    <arm_group_label>Phenazopyridine</arm_group_label>
    <other_name>Pyridium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females only

          -  Planned surgical procedure where cystoscopy will be used to document ureteral urine
             flow

          -  Age &gt; or = 18 years, no upper age limit

          -  Able and willing to consent

        Exclusion Criteria:

          -  Planned surgical procedure where cystoscopy will not be used

          -  Planned surgical procedure where cystoscopy is used for a purpose other than
             documenting ureteral urine flow

          -  age &lt;18 years

          -  pregnancy

          -  unable/unwilling to participate

          -  history of allergy or adverse reaction to phenazopyridine

          -  hepatic dysfunction

          -  known phenazopyridine hypersensitivity

          -  history of urologic surgery

          -  presence of ureteral stents prior to the planned surgical procedure

          -  concomitant suprapubic catheter placement
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <results_first_submitted>August 15, 2016</results_first_submitted>
  <results_first_submitted_qc>October 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2016</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Katie Propst</investigator_full_name>
    <investigator_title>Fellow</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>No preoperative phenazopyridine</description>
        </group>
        <group group_id="P2">
          <title>Phenazopyridine</title>
          <description>Preoperative oral phenazopyridine: two tablets 97.5 mg each (195 mg total)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>surgery cancelled</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>No preoperative phenazopyridine</description>
        </group>
        <group group_id="B2">
          <title>Phenazopyridine</title>
          <description>Preoperative phenazopyridine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="11.3"/>
                    <measurement group_id="B2" value="62.7" spread="9.8"/>
                    <measurement group_id="B3" value="60.19" spread="10.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson comorbidity index</title>
          <description>The Charlson co-morbidity index is a scale used in longitudinal studies to estimate relative risk of death from prognostic clinical covariates. Age and comorbidities are evaluated to produce a score. Minimum score is zero, there is no maximum score. Zero is predicts no risk of death based on age and comorbidities.</description>
          <units>scale score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.96" spread="1.5"/>
                    <measurement group_id="B2" value="2.31" spread="1.1"/>
                    <measurement group_id="B3" value="2.13" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.66" spread="0.28"/>
                    <measurement group_id="B2" value="0.63" spread="0.35"/>
                    <measurement group_id="B3" value="0.65" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History or prolapse surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of urinary tract surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical indication: prolapse</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical indication: incontinence</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage II or greater prolapse: anterior</title>
          <description>Pelvic organ prolapse is assessed by physical exam using the Pelvic Organ Prolpase Quantification scale. The results of the exam findings are then classified into prolapse stages which range from 0 (no prolapse ) to IV (complete prolapse). Each compartment (anterior / bladder, apical / uterus / vaginal cuff, and posterior / rectum) is assigned a stage.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage II or greater prolapse: apical</title>
          <description>Pelvic organ prolapse is assessed by physical exam using the Pelvic Organ Prolpase Quantification scale. The results of the exam findings are then classified into prolapse stages which range from 0 (no prolapse ) to IV (complete prolapse). Each compartment (anterior / bladder, apical / uterus / vaginal cuff, and posterior / rectum) is assigned a stage.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage II or greater prolapse: posterior</title>
          <description>Pelvic organ prolapse is assessed by physical exam using the Pelvic Organ Prolpase Quantification scale. The results of the exam findings are then classified into prolapse stages which range from 0 (no prolapse ) to IV (complete prolapse). Each compartment (anterior / bladder, apical / uterus / vaginal cuff, and posterior / rectum) is assigned a stage.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical procedure performed: concomitant incontinence procedure</title>
          <description>Number of participants who underwent an incontinence procedure in addition to surgery for pelvic organ prolapse</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical procedure performed: prolapse repair without hysterectomy</title>
          <description>Subjects who underwent surgical treatment of pelvic organ prolapse without a concomitant hysterectomy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical procedure performed: prolapse repair with vaginal hysterectomy</title>
          <description>Number of study participants who underwent surgical repair of pelvic organ prolapse with a concomitant vaginal hysterectomy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical procedure performed: prolapse repair with abdominal hysterectomy</title>
          <description>Number of study participants who underwent surgical repair of pelvic organ prolapse with a concomitant abdominal hysterectomy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical procedure performed: prolapse repair with laparoscopic hysterectomy</title>
          <description>Number of study participants who underwent surgical repair of pelvic organ prolapse with a concomitant laparoscopic hysterectomy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Visualize Ureteral Urine Flow Intraoperatively Measured by Timing in the Operating Room</title>
        <description>Timing was performed in the operating room. Time to visualize urine efflux was started at insertion of the cystoscope into the bladder, the time was considered complete when both ureteral orifices had displayed urine efflux.</description>
        <time_frame>Day of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No preoperative phenazopyridine</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Preoperative oral phenazopyridine: two tablets 97.5 mg each (195 mg total)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Visualize Ureteral Urine Flow Intraoperatively Measured by Timing in the Operating Room</title>
          <description>Timing was performed in the operating room. Time to visualize urine efflux was started at insertion of the cystoscope into the bladder, the time was considered complete when both ureteral orifices had displayed urine efflux.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" spread="158"/>
                    <measurement group_id="O2" value="173" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Confidence Measured by a Survey</title>
        <description>Surgeon response to the question: &quot;I am confident that ureteral injury was ruled out in this patient&quot; on a 5-point Likert scale where 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree</description>
        <time_frame>day of surgery (day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No preoperative phenazopyridine</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Preoperative oral phenazopyridine: two tablets 97.5 mg each (195 mg total)</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Confidence Measured by a Survey</title>
          <description>Surgeon response to the question: &quot;I am confident that ureteral injury was ruled out in this patient&quot; on a 5-point Likert scale where 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly agree</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="0.49"/>
                    <measurement group_id="O2" value="4.5" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Interventions: Measured by Use of IV Fluids, IV Lasix, IV Methylene Blue, or Ureteral Stent Placement in OR</title>
        <description>this is a composite measure and will be reported as a single value for each arm as number of additional interventions</description>
        <time_frame>day of surgery (day 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No preoperative phenazopyridine</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Preoperative oral phenazopyridine: two tablets 97.5 mg each (195 mg total)</description>
          </group>
        </group_list>
        <measure>
          <title>Additional Interventions: Measured by Use of IV Fluids, IV Lasix, IV Methylene Blue, or Ureteral Stent Placement in OR</title>
          <description>this is a composite measure and will be reported as a single value for each arm as number of additional interventions</description>
          <units>interventions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Urethral Discomfort Measured by Pain Scales</title>
        <description>Measured prior to catheter removal using a 10 point visual analog pain scale: Zero represented no pain, Ten represented the most severe pain.</description>
        <time_frame>post operative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No preoperative phenazopyridine</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Preoperative oral phenazopyridine: two tablets 97.5 mg each (195 mg total)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Urethral Discomfort Measured by Pain Scales</title>
          <description>Measured prior to catheter removal using a 10 point visual analog pain scale: Zero represented no pain, Ten represented the most severe pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.8"/>
                    <measurement group_id="O2" value="2.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trial of Void Results</title>
        <description>Number of subjects that failed a back-filled trial of void on the day of hospital discharge, up to 2 days after surgery.</description>
        <time_frame>Day of hospital discharge</time_frame>
        <population>For this outcome, 96 participants were analyzed. Of the 104 participants that completed the study, only 96 underwent a trial of void.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No preoperative phenazopyridine</description>
          </group>
          <group group_id="O2">
            <title>Phenazopyridine</title>
            <description>Preoperative oral phenazopyridine: two tablets 97.5 mg each (195 mg total)</description>
          </group>
        </group_list>
        <measure>
          <title>Trial of Void Results</title>
          <description>Number of subjects that failed a back-filled trial of void on the day of hospital discharge, up to 2 days after surgery.</description>
          <population>For this outcome, 96 participants were analyzed. Of the 104 participants that completed the study, only 96 underwent a trial of void.</population>
          <units>participants who failed trial of void</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of surgery to 30 days post-surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>No preoperative phenazopyridine</description>
        </group>
        <group group_id="E2">
          <title>Phenazopyridine</title>
          <description>Preoperative phenazopyridine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katie Propst, MD</name_or_title>
      <organization>Hartford Hospital</organization>
      <phone>860-972-4338</phone>
      <email>katie.propst@hhchealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

